Connect with us

Foreign News

India’s Pharma 2.0: Going Beyond Generics

Published

on

India’s Pharma 2.0: Going Beyond Generics

India is already known as the Pharmacy of the World, supplying affordable medicines to over 200 countries and producing one in every five generic drugs consumed globally.

But the future of healthcare is moving rapidly toward biologics, AI-driven drug discovery, precision medicine, and next-generation therapeutics.

In this episode hosted by StratNewsGlobal.Tech, Anil Padmanabhan speaks with Dr. Pravarkar Sahoo, Programme Director at NITI Aayog and lead author of the latest Trade Watch Quarterly, which put the spotlight on how India could transition from a global pharma manufacturing powerhouse to a global pharmaceutical innovation hub.

Key topics covered:

  • Why India has only managed to capture a mere 2.8% of global pharma value;
  • The shift from generics to biologics;
  • India’s dependence on China for APIs;
  • GLP-1 drugs and the next wave of pharmaceutical innovation;
  • Hyderabad’s emergence as a global life sciences hub;
  • What Pharma 2.0 means for India’s economy.
Previous articleIndia Moves Into Phase 2.0 Of Chip-Making, $13 Bn Budget, Strategic Intent
Anil Padmanabhan

Anil Padmanabhan has been a journalist for the last 36 years. He has worked in various capacities in several publications including Afternoon Despatch & Courier, Press Trust of India, Business Standard, Mint and was based in New York for India Today. He was a Nieman Fellow in 2001. He tweets at @capitalcalculus.

Source link

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *